BIRMINGHAM, Ala., March 6, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.
Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will participate in a fireside chat on Wednesday, March 15, 2023, from 9:00 - 9:25 a.m. ET.
The presentation will be webcast live and available at http://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Casey Winger| 205.970.5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205.970.5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$120.99 |
Daily Change: | -1.64 -1.34 |
Daily Volume: | 529,479 |
Market Cap: | US$12.190B |
June 18, 2025 April 24, 2025 April 24, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load